Andy S. Stergachis
Andy Stergachis, Ph.D., M.S., directs the Global Medicines Program in the Department of Global Health at the University of Washington (UW). He is professor of Pharmacy and Global Health and an associate dean in the School of Pharmacy. His research focuses on pharmacoepidemiology, global drug and vaccine safety, and pharmaceutical outcomes research. He is author of 158 peer-reviewed publications in areas such as pharmacovigilance, pharmacoepidemiology, pharmaceutical outcomes, and clinical epidemiology and serves as Editor-in-Chief of the Journal of the American Pharmacists Association. He presently serves as a co-investigator with the UW Institute for Health Metrics and Evaluation for a study on Mapping and Monitoring the Global Burden of Antimicrobial Resistance. He recently directed a study on the safety of antimalarial drugs used during pregnancy conducted in three sub-Saharan African (SSA) countries and has developed novel approaches for malaria and HIV pharmacovigilance and strengthening pharmacy services in SSA. Through his affiliation with the Northwest Center for Public Health Practice, he works on workforce development and public health systems research in emergency preparedness with the public health community. He is also affiliated with the UW Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute. He is Chair of the Expert Panel to Review Surveillance and Screening Technologies for the Quality Assurance of Medicines for USP, Chair of the Low-dose Primaquine Safety Study Group for the WorldWide Antimalarial Resistance Network, and has served as member of the Access and Product Management Advisory Committee for Medicines for Malaria Venture. He is a Fellow of the International Society for Pharmacoepidemiology and Fellow of the American Pharmacists Association-Academy of Pharmaceutical Research and Science. Dr. Stergachis is a member of the National Academy of Medicine (elected 2012). He has served on numerous National Academies’ committees, including the Committee on Interactions of Drugs, Biologics, and Chemicals in U.S. Military Forces and the Committee on the Assessment of the U.S. Drug Safety System. Dr. Stergachis received his bachelors of pharmacy from Washington State University and both his master’s degree in pharmacy administration and his doctorate in social an administrative pharmacy from the University of Minnesota.
Elizabeth A. Stuart
Elizabeth Stuart, Ph.D., is a professor in the Department of Mental Health in the Johns Hopkins Bloomberg School of Public Health with joint appointments in the Departments of Biostatistics and Health Policy and Management, and she is also the associate dean for education at JHSPH. Dr. Stuart has an undergraduate degree in mathematics from Smith College and completed her Ph.D. in statistics at Harvard University. Her research has addressed several areas in public health including mental health services, health care policy evaluation, and long-term effects of substance abuse. Her research focuses on the use of different design and analysis methods for estimating causal effects, especially in terms of improving the internal validity of non-experimental studies and the external validity of randomized studies. She also researches methods for addressing missing data and non-compliance, and has made important contributions to collaborative and methodological research in the area of causal inference applied to mental health and psychology. Dr. Stuart is also affiliated with several other Johns Hopkins centers including Drug Safety and Effectiveness, Mental Health and Addiction Policy Research, and the Bloomberg American Health Initiative. She is an Elected Fellow of the American Statistical Association, for which she was a founding member of the Mental Health Statistics Section and has received the Gertrude Cox Award for applied statistics and the Myrto Lefkopoulou award from the Harvard University Department of Biostatistics. She is an associate editor and reviewer for several journals related to statistics, epidemiologic methods, and mental health, and she has contributed to nearly 200 peer-reviewed publications. She has consistently been recognized for her outstanding abilities in teaching, and has received several awards for her teaching and research. Dr. Stuart has previously served as a panel member for the National Academies on an activity related to methodologies for studying commercial motor vehicle driver fatigue.
Carol A. Tamminga
Carol Tamminga, M.D., is a professor, chairman of Psychiatry and chief of Translational Neuroscience Research in Schizophrenia at the University of Texas Southwestern Medical School. She holds the Communities Foundation of Texas Chair in Brain Science along with the Lou and Ellen McGinley Distinguished Chair in Psychiatric Research. She directs clinical and preclinical research in schizophrenia focused on identifying disease mechanisms and on improving treatments. Dr. Tamminga graduated from Vanderbilt Medical School and completed a psychiatry residency at the University of Chicago and spent many years at the University of Maryland, MPRC, then moved to UT Southwestern Medical School to continue her research. Dr. Tamminga has been the recipient of numerous federal and foundation grants, as well as awards in the field. She has served on the National Advisory Mental Health Council, NIMH and the Council of the National Institute of Drug Abuse. Dr. Tamminga was elected to the National Academy of Medicine in 1998 and has served on several IOM committees in that capacity. The goal of Dr. Tamminga’s research is to examine and understand the mechanisms underlying schizophrenia, especially its most prominent symptoms, psychosis and memory dysfunction, in order to build rational treatments for the illness. She evaluates the function of the living human brain in individuals with and without schizophrenia using brain imaging techniques. Then, building on this knowledge, she uses human postmortem brain tissue to translate the functional alterations from the living human patient into molecular observations of the illness. Now she is using case-specific neuronal cultures to address molecular and cellular questions. Her ultimate goal is to use the alterations in in vivo imaging, postmortem molecular changes and cultured neuronal characteristics as biomarkers and targets for identifying animal models of disease and novel active pharmaceuticals for psychosis.
Jonathan L. Vennerstrom, Ph.D., is a professor in the Department of Pharmaceutical Sciences in the College of Pharmacy at the University of Nebraska Medical Center. He received his Ph.D. in medicinal chemistry from the University of Minnesota, and completed his post-doctoral training at Walter Reed. Dr. Vennerstrom’s work focuses on anti-infective drug discovery, particularly the medicinal chemistry of antiparasitic agents and the investigation of heme as a mechanistic intersection for antimalarial drugs. His work has led to the discovery of new mechanisms of action of chloroquine (and other antimalarial quinolines) and new understanding of mechanisms of how hemozoin is formed in the malaria parasite. His research has comprehensively characterized the structural features of chloroquine associated with its antimalarial properties, and shown that peroxide antimalarial activity depends upon parasite hemoglobin digestion. Two antimalarial drug candidates were discovered during his work with the Medicines for Malaria Venture; one is now available in India and the other is in Phase IIb trials as a potential single-dose malaria treatment; both of these drugs are outside of the committee’s statement of task. Dr. Vennerstrom continues to use the knowledge generated by his research in order to discover other antimicrobial drug candidates for several infectious diseases, including malaria. He is a member of the American Society for Microbiology, the American Society of Tropical Medicine and Hygiene, and the American Chemical Society from which he received the ACS Award for Creative Innovation in 2019. He has received several other awards including the two-time recipient of the Medicines for Malaria Venture Project of the Year Award (2001, 2006), Alvin M. Earle Outstanding Health Science Educator Award, University of Nebraska Medical Center Distinguished Scientist Award, UNeMed Lifetime Achievement Award, and the University of Nebraska Innovation, Development, and Engagement (IDEA) Award. His work continues to drive innovation in the drug discovery field. Dr. Vennerstrom has authored or co-authored more than 150 peer-reviewed journal articles.
Christina M. Wolfson
Christina M. Wolfson, Ph.D., is a professor in the Department of Medicine and the Department of Epidemiology, Biostatistics and Occupational Health, at McGill University and senior scientist in the Brain Repair and Integrative Neuroscience (BRAIN) Program at the Research Institute of the McGill University Health Centre. She is an associate member in the Departments of Neurology and Neurosurgery, and Mathematics and Statistics at McGill University. A neuroepidemiologist, her program of research lies in population-based research in neurodegenerative disorders including multiple sclerosis, Parkinson’s disease, and epilepsy. She is co-Principal investigator on the Canadian Longitudinal Study on Aging, a 20-year study of 50,338 participants aged 45-85 in which she leads the Neurological Conditions Initiative and the Veterans’ Health Initiative and is the Director of the CLSA Statistical Analysis Centre. Dr. Wolfson is co-principal investigator on a 5-country MS risk factor study (Environmental Risk Factors in Multiple Sclerosis - EnvIMS) completed in Italy, Norway, Serbia, Sweden and Canada. She is also the Program Director of the endMS National Training Program.
Dr. Wolfson received her undergraduate degree in mathematics, her master’s degree in mathematical statistics, and her Ph.D. in epidemiology and biostatistics from McGill University. She has published over 220 peer-reviewed journal articles and has previously served as a member on four National Academies’ consensus committees related to health effects in U.S. veterans that served in the 1990-1991 Gulf War and Post 9/11 conflicts.